OVID (Ovid Therapeutics) Risk Assessment


OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.67
GF Value $8.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ovid Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Ovid Therapeutics is: High Risk: High uncertainty.

Ovid Therapeutics  (NAS:OVID) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Ovid Therapeutics Risk Assessment Related Terms

OVID vs ARTV, CCCC, RZLT: Risk Assessment Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovid Therapeutics Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Risk Assessment falls into.


OVID
48GF Score
Ovid Therapeutics Inc OVID
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.67 is trading 68.4% below its estimated GF Value™ of $8.46. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • Risk Assessment:
  • GF Value™: $8.46 vs. price of $2.67 (68.4% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.67
Price
$8.46
GF Value